What’s New in AML: Menin Inhibitors Explained
Menin inhibitors are a newly approved class of treatments for certain types of AML. In this AML patient webinar, Dr. Eunice Wang will explain what menin inhibitors are, review recent approvals, and discuss important differences between the available options, so you can better understand where they may fit into your AML care.
Mary introduces the agenda for the event and featured speaker Dr. Eunice Wang
Dr. Wang will talk about menin inhibitors.
Type your questions in the chat and we will answer them!
Mary Arnett
Mary joined HealthTree in 2022 as a part of HealthTree's team to help expand into all blood cancers. She now works as HealthTree's Volunteer & Community Outreach Manager, helping to engage and involve community members in HealthTree's mission. When she isn't working, she loves being the fun aunt to her 13 nieces and nephews, attending concerts, experimenting with new recipes in the kitchen, and traveling to explore new cities.
Eunice Wang, MD
Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang’s clinical research focuses on the development of early stage clinical trials for acute leukemias (AML, ALL) and myeloproliferative disorders. Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies. Dr. Wang has authored/co-authored over 90 peer-reviewed articles, multiple book chapters, and editorials. In addition to her research, Dr. Wang maintains an active clinical practice.